ArticleProbiotics and antimicrobial proteins2026
Characterization of a Phage vB_LZ 2044 Deriving from K1-Type Hypervirulent Klebsiella pneumoniae Efficient Against Liver Infection Mice Model.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Modular plug-and-play engineering of Klebsiella phages with dual receptor-binding proteins for efficient host range design.Journal of biological engineering · 2026Article
- Therapeutic efficacy of a K1-specific bacteriophage against hypervirulent Klebsiella pneumoniae in a mouse infection model.Virologica Sinica · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In order to address the issue of antimicrobial resistance posed by hypervirulent Klebsiella pneumoniae (hvKp), bacteriophages that selectively target and lyse the bacteria are being investigated as a promising therapeutic option for the treatment of clinical infections associated with hvKp. The phage vB_LZ 2044, which was isolated and characterized utilizing hvKp NTUH-K2044 as the host strain, demonstrates significant efficacy against nine distinct K1 serotype Klebsiella pneumoniae strains and exhibits an impressive lysing capacity of 396.7 PFU/cell at burst size. Moreover, it displays remarkable stability across a wide pH range (pH 4-10) and temperature range (4-40 °C), positioning it as a promising antimicrobial agent. Genetic analysis has revealed that vB_LZ 2044 is a 50419 bp double-stranded DNA phage classified under the genus Webervirus within the family Drexlerviridae. The putative Open Reading Frames (ORFs) encoded by the phage, including the perforin-endolysin-spanin system protein (ORF26, ORF27, ORF28) and the peptin lyase folds containing the tailspike protein (ORF10), are crucial for lysing the host bacteria. Furthermore, experiments conducted on mice have demonstrated the effectiveness of vB_LZ 2044 in treating hvKp-induced liver infections without inflicting additional damage to the liver tissues, thus preserving the integrity of the liver structure and mitigating inflammation. The stable biological properties and pronounced antimicrobial effects observed in the mice model suggest that phage vB_LZ 2044 holds significant potential for development as a novel antimicrobial agent.
Indexed as
Identifiers
40560474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.